

Research Article

The Correlation of Serum Growth Differentiation Factor-15 Level in Patients with Obstructive Sleep Apnea

Kamran Sari,¹ Huseyin Ede,² Zeliha Kapusuz Gencer,¹ Mahmut Ozkiris,¹ Ayse Yesim Gocmen,³ and Yavuz Selim Intepe⁴

¹Otorhinolaryngology Department, Bozok University School of Medicine, 66200 Yozgat, Turkey

²Cardiology Department, Bozok University School of Medicine, 66200 Yozgat, Turkey

³Biochemistry Department, Bozok University School of Medicine, 66200 Yozgat, Turkey

⁴Chest Disease Department, Bozok University School of Medicine, 66200 Yozgat, Turkey

Correspondence should be addressed to Kamran Sari; ksari77@hotmail.com

Received 8 February 2015; Accepted 14 April 2015

Academic Editor: Quintin Pan

Copyright © 2015 Kamran Sari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Growth differentiation factor-(GDF-) is a prognostic biomarker in cardiovascular disorders (CVD). GDF-15 level was not studied in patients with obstructive sleep apnea syndrome (OSAS) before. In this study, we investigated serum GDF-15 levels in OSAS patients and compared them with healthy controls. *Material and Methods.* Polysomnographically, confirmed forty consecutive OSAS patients (20 men and 20 women) and forty consecutive healthy controls (23 men and 17 women) were enrolled in the study. The samples in each group had similar demographic characteristics and body mass index (BMI) values. *Results.* In the study, no significant correlation was found about GDF-15 levels of OSAS group and healthy controls. However, there was a significant statistical correlation between age and GDF-15 level. In correlation analysis, there was not any significant correlation between age and BMI. *Conclusion.* Although various developing biomarkers have been studied in cardiovascular disorders, GDF-15 levels have attracted a widespread interest as predictors of cardiovascular risk. GDF-15 level has not been evaluated previously in patients with OSAS. A significant statistical correlation was found between age and GDF-15 level. To reveal close relation between OSAS and GDF-15, further studies are needed with combination of GDF-15 and other biomarkers in OSAS.

1. Introduction

Obstructive sleep apnea syndrome (OSAS) is characterized by frequent sessions of collapse of upper airways during sleep, resulting in recurrent episodes of intermittent hypoxemia and arousal from sleep [1–3]. Its incidence rises increasingly in the society. It influences approximately 24% of men and 9% of women [4]. OSAS leads to an increase in metabolic and cardiovascular problems if untreated [5, 6]. In a meta-analysis, Wang et al. showed that severe OSAS is significantly and independently associated with an increased risk of cardiovascular disease (CVD), stroke, and all-cause mortality [7]. Takama and Kurabayashi [8] reported that the presence of OSAS was a strong predictor of fatal cardiovascular events in patients with CVD. Growth-differentiation factor-15 (GDF-15) is a secreted protein, which is a member of the transforming growth factor- β (TGF- β) cytokine superfamily [9].

GDF-15 is not expressed in the adult myocardium at normal circumstances. But its expression is strongly induced in the heart during experimental ischaemia and reperfusion injury [10]. GDF-15 is highly expressed in the placenta and the prostate, but its level is not normal in many other organs like heart [8, 9]. GDF-15 has recently been defined as a protein that is upregulated in cardiac myocytes by simulated ischaemia, reactive oxygen species, and proinflammatory cytokines [10, 11]. Kempf et al. [12] have recently found that patients with chronic heart failure (CHF) have increased circulating levels of GDF-15. It is also upregulated by some cardiovascular events triggering oxidative stress, heart failure, and atherosclerosis [11, 13].

We hypothesized that serum GDF-15 level may be increased in patients with OSAS because of the relation between OSAS and CVD. In this study, we searched for serum GDF-15 level in patients with OSAS and compared it to that

of the patients without OSAS. To the our best knowledge, this is the first study investigating the association between OSAS and GDF-15 level.

2. Material and Methods

This prospective, case-control study was performed with cooperation of Otolaryngology, Cardiology, Chest and Biochemistry Departments of Bozok University School of Medicine. Between February 2014 and September 2014, a total of 150 patients were evaluated in suspect of OSAS. Of 150, forty patients who were diagnosed with OSAS were enrolled in the study. The control group consisted of forty healthy samples. All patients and controls were examined by the Ear, Nose, Throat and Chest departments to validate inclusion criteria before the study. Patients were not included in the study if they have had any of the following disease or disorders: presence of CVD, congenital abnormalities of the head and neck region, recent head trauma, neurologic or metabolic diseases (epilepsy, diabetes mellitus), history of previous use of sedatives and muscle relaxants in the last 3 months, sleep disorders other than OSAS (e.g., restless legs syndrome, insomnia), and any pulmonary disorders.

The participants were given information about the study according to Helsinki Declaration. Approval of the institutional ethics committee was obtained from Bozok University School of Medicine Ethics Committee on Non-Interventional Clinical Investigation.

Polysomnographically, confirmed 40 consecutive OSAS patients (20 men and 20 women) with an average age of 48 years (18–63 years) and 40 consecutive control subjects (23 men and 17 women) with an average age of 46 years (29–65 years) were recruited for the study. The subjects in each group had similar demographic characteristics and body mass index (BMI) values. Weight and height measurements were used to calculate BMI (kg/m^2) values. BMI $> 30 \text{ kg}/\text{m}^2$ was defined as obesity. Routine physical and otolaryngological examinations were performed in both groups. Polysomnographic evaluation was found normal in the control group (apnea/hypopnea index (AHI) < 5).

According to the polysomnographic evaluation, an apnea/hypopnea index (AHI) equal or more than five per hour of sleep was used to diagnose OSAS. Apnea was defined if airflow dropped below 10% of the reference amplitude for 10 seconds. If airflow dropped below 70% for 10 seconds with a following oxygen desaturation of 4% or more, it was defined as hypopnea. The AHI index was calculated with the average number of apneas and hypopneas per hour of sleep. At polysomnographic analysis, electrocardiography, oronasal airflow measurement, duration of snoring periods, thoracic and abdominal respiratory movements, body position changes, and oxygen saturation (pulse oximeter) were measured and recorded simultaneously with the sleep stages by electroencephalography, electrooculography, and chin and tibial electromyograms. Sleep stages were scored according to the standard criteria of American Academy of Sleep Medicine (AASM) criteria. Patients with AHI < 5 were evaluated as normal while patients with AHI ≥ 5 were defined as OSAS.

An AHI score between 5 and 15 indicated mild OSAS, 16 to 30 indicated moderate OSAS, and ≥ 30 indicated severe OSAS [14].

3. Blood Sampling and Laboratory Analyses

After an overnight fasting, venous blood samples were collected. Within an hour of venipuncture, whole blood samples were centrifuged and separated, and serum portions were frozen at -80°C for future analysis. Serum GDF-15 levels were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (BioVendor, Brno, Czech Republic).

3.1. Statistical Analyses. Statistical analyses were performed using the SPSS package programme. Continuous variables are expressed in mean \pm SD and categorical variables are presented as frequencies (%). Normality of variables was tested with Kolmogorov-Smirnov test. Age and BMI values did show normal distribution while GDF-15 did not show normal distribution. Thus, Pearson and Spearman tests were used for correlation analyses accordingly, and Mann-Whitney *U*-test and student's *t*-test were used to compare groups accordingly. Categorical variables of the groups were compared using the chi-square test. A *p* value of less than 0.05 was considered to show statistically significant result.

4. Results

In the study, we did not find any significant difference between OSAS patients and controls in respect to BMI ($p > 0.05$). The control and OSAS group demonstrated average AHI levels of 2,32 and 36,77, respectively. Sixteen patients had severe OSAS (AHI III), twelve patients with moderate OSAS (AHI II), and twelve patients with mild OSAS (AHI I). In correlation analysis, we did not find any significant correlation between age and BMI ($p = 0.531$; $r = 0.071$). However, there was a significant statistical correlation between age and GDF-15 level ($p = 0.468$, $r = 0.000$). Oppositely, GDF-15 did not show any statistical correlation to BMI ($p = 0.697$, $r = 0.044$). The average GDF-15 levels of OSAS group and control group were found to be 413 ng/L and 410 ng/L, respectively (Figure 1). The demographic characteristics and average level of GDF-15 of the groups were statistically similar and expressed in Table 1.

5. Discussion

GDF-15 is a protein that belongs to TGF- β superfamily. GDF-15 level is induced by IL-1, TNF- α , and TGF- β in macrophages in turn. It restricts macrophage activation and inflammation. In addition, injury, oxidative stress and atherosclerosis can increase secretion of GDF-15. Increasing levels of GDF-15 stimulate anti-inflammatory effect on macrophage, antiapoptotic effect on some cancer cells, and antigrowth and antihypertrophic effect at inhibition of remodeling [15]. Although numerous emerging biomarkers have been studied in cardiovascular events, GDF-15 levels




FIGURE 1: The average GDF-15 levels of OSAS group and control group.

TABLE 1: Demographic characteristics and median level of GDF-15 in OSA and control groups.

	The control group (n = 40)	The study group (n = 40)
Mean age (in year)	46 ± 9	48 ± 10
Gender (male/female) (%)	23/17 (57/43)	20/20 (50/50)
Body mass index (kg/m ²)	29.9 ± 3.9	32.0 ± 6.2
GDF-15	410 ng/L ± 159	413 ng/L ± 170

have attracted a widespread interest as predictors of cardiovascular risk. It is pointed that GDF-15 level is associated with the risk of death and myocardial infarction independent of clinical variables and other biomarkers [16]. Dominguez-Rodriguez et al. [17] measured the level of GDF-15 and high-sensitivity C-reactive protein (hsCRP) in patients with acute coronary syndrome at admission and again 36 months after admission. They found that the change of hsCRP levels, measured after 36 months, does not estimate major cardiovascular adverse events (MACE) in patients with acute coronary syndrome. But the level of GDF-15 measured, after 36 months, was a significant predictor of MACE in acute coronary syndrome patients. In a study by Bonaterra and colleagues [18] about GDF-15 knockout mice, it was shown that GDF-15 deficiency protects mice against atherosclerosis. They explained that GDF-15 deficiency results in inhibition of atherosclerosis progression in hypercholesterolemic mice. They also stated that IL-6 plays a major role in the progression of atherosclerosis. In the same study, they showed that GDF-15 is upregulated in the atherosclerotic vessel wall. A recent study found evidence that GDF-15 is associated with infarct size in experimental heart attack models [19].

We think that GDF-15 might be a novel strong biomarker in cardiovascular diseases like heart attack or atherosclerosis. And this hypothesis is supported by a recent study on the association of GDF-15 and coronary diseases [20].

OSAS is a common disorder 22% in the general population aged 50–80 years and defined as AHI > 5/h [21]. Its

prevalence increases with age. It is known that OSAS can cause cardiovascular and metabolic dysfunctions by inflammatory cytokines upregulation [4]. The period of intermittent hypoxia and carbon dioxide retention creates imbalance in the relation between sympathetic and parasympathetic nervous regulation [22]. This imbalance increases the heart rate and systemic blood pressure (BP) with sympathetically mediated peripheral vasoconstriction [23]. Intermittent chronic hypoxia and oxidative stress can play role in the induction of reactive oxygen radicals production, inflammatory cytokines release, and endothelial dysfunction in patients with OSAS [4]. On long term, OSAS leads to repetitive nocturnal hypoxia and sleep disturbance. This condition induces an increase in cytokine and inflammatory markers [22]. It is accepted that proinflammatory cytokines and oxidative stress increase GDF-15 secretion. Therefore, we thought that chronic hypoxia and oxidative stress caused by OSAS may lead to an increase in the level of GDF-15.

To the best of our knowledge, this is the first study investigating the association between OSAS and GDF-15 level in a case-control study of women and men. In the present study, we investigated the level of GDF-15 in patients with OSAS and healthy controls. We found similar results in each group. Also our data showed that there was a positive correlation between age and GDF-15 level. GDF-15 level has been found to be increased with aging. It can be due to increased incidence of atherosclerosis, heart failure, and other pathologies with aging that trigger oxidative stress. All of these pathologies increase the level of GDF-15. In a study related to GDF-15 level in ST-segment elevation myocardial infarction (STEMI), Kempf et al. [24] showed that GDF-15 levels were independently related to age, male gender, diabetes, smoking, reduced systolic blood pressure, elevated heart rate, and a cardiac troponin T (cTnT) level at presentation. They discovered that GDF-15 is a new biomarker in STEMI that ensures prognostic information about the disease. They found that increasing levels of GDF-15 were associated with increased age. The upper limit of normal level of GDF-15 is less than 1200 ng/L. In our study, GDF-15 levels were found less than 1000 ng/L in both groups. In an another study by Kempf et al. [12], they found that GDF-15 levels also increases in patient with low body mass index and in patients with myocardial infarction, ischemic etiology, higher New York Heart Association (NYHA) functional class, and a reduced left ventricular ejection fraction (LVEF). In our study, we did not find any correlation between GDF-15 level and BMI.

BMI is another factor that affects GDF-15 level. In a study concerning obesity and GDF-15 level, it was found that GDF-15 levels were higher in obese group than in nonobese group [25]. In our study, BMI levels were similar in both OSAS and the control groups (32 kg/m² and 29.9 kg/m², resp.). Average GDF-15 levels were similar between groups and under 1200 ng/L. In recent studies, it was pointed that GDF-15 level is higher in men than women [24]. In our study, GDF-15 level is higher in men than women, but the difference was not statistically significant. The relation between OSAS categories and GDF-15 levels was analyzed, and significant difference was not found in respect to OSAS categories.

In many numerous studies, different kinds of cardiac markers were investigated in OSAS patients [26, 27]. Randby et al. [27] examined High-Sensitivity Cardiac Troponin T (hs-cTnT) level in patients with OSAS. They categorized the subjects according to AHI levels that correspond to no, mild to moderate, and severe OSAS. They found that the proportion of subjects with detectable hs-cTnT levels increased with increasing severity of OSAS. Even so, there was no independent correlation between AHI and detectable hs-cTnT after the correction for all significant univariate covariates. They interpreted that a clustering of cardiovascular risk factors clarifies the observed association between hs-cTnT levels and the severity of OSAS. C-reactive protein (CRP) is a common inflammatory biomarker. It has been synthesized by hepatocytes in response to inflammatory process. Also, CRP could have been synthesized in coronary artery smooth muscle and adipose tissue [28]. In healthy persons, CRP is a predictor in CVD. It has been studied in patients with OSAS. But the results are controversial [29]. According to a recent meta-analysis, it has been shown that CRP was higher in patients with OSA than control group [30]. Moreover, in another meta-analysis, evidence was found that treatment with continuous positive airway pressure (CPAP) could partly suppress inflammation [31]. Hall and colleagues [32] measured level of CRP and myeloid-related protein-8/14 (MRP-8/14) in patients with OSAS and investigated the relation between obesity and inflammatory parameter. They did not find any definitive indication of independent immunological activity between apneas and hypopneas and inflammatory factors. But they found that average oxygen saturation for MRP-8/14 and oxygen desaturation index for CRP stranded statistically significant predictors. Also they found that CRP was strongly correlated with BMI. Interleukin-6 (IL-6) interleukin-1 beta (IL-1b), and tumor necrosis factor-alpha (TNF- α) are one of the important atherogenic markers in ischemic stroke patients. OSAS is seen common especially in acute stroke patients. Medeiros et al. [33] found that IL-6 shows a mean rise in stroke patients with OSAS. It was thought that this inflammatory marker may play a role in the mechanism of atherogenic and endothelial dysfunction in the relationship between OSA and cerebrovascular disease. In their study, serum IL-6 levels were independently negative correlated with desaturation index and low SpO₂ values. There was no relation between inflammatory biomarkers and AHI in their study.

Inami et al. [22] examined the relation between sleep disordered breathing (SDB) and the severity of coronary artery disease (CAD). They analyzed the relation between SDB, coronary atherosclerotic burden, and cardiac biomarkers in stable CAD patients. They showed that N-terminal pro-B-type natriuretic peptide (NT-proBNP) and hs-TnT levels increased in patients with CAD and SDB. In our study, the patients with OSAS did not have CAD. Thus, GDF-15 level may have been fixed within normal range.

In our study, there was not any significant difference between groups in respect to GDF-15 level. One reason for this, the ratio of patients with severe OSAS were 40% in the OSAS group. There would be significant difference between groups in respect to GDF-15 level if all of the OSAS group

consisted of patients with severe OSAS. Considering relation of BMI and GDF-15, no significant correlation was found among the subjects, because we matched BMI values of groups in order to remove any effects of obesity on OSAS.

GDF-15 is an important biomarker in cardiovascular pathologies. GDF-15 level has not been evaluated previously in patient with OSAS. In this study, we found similar GDF-15 levels between OSAS group and the control group. However, we found a significant statistical correlation between age and GDF-15 level. To show the relation between OSAS and GDF-15, we suggest further studies with combination of GDF-15 and other biomarkers in OSAS.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported by Bozok University Science and Technology Support Program of Turkey. The authors thank the board of directors of the Bozok University for the funding support.

References

- [1] T. Young, E. Shahar, F. J. Nieto et al., "Predictors of sleep-disordered breathing in community-dwelling adults: The Sleep Heart Health Study," *Archives of Internal Medicine*, vol. 162, no. 8, pp. 893–900, 2002.
- [2] J.-D. L. Lattimore, D. S. Celermajor, and I. Wilcox, "Obstructive sleep apnea and cardiovascular disease," *Journal of the American College of Cardiology*, vol. 41, no. 9, pp. 1429–1437, 2003.
- [3] Z. K. Gencer, M. Özkiriş, Y. Göçmen et al., "Erratum to: the correlation of serum levels of leptin, leptin receptor and NO_x (NO₂⁻ and NO₃⁻) in patients with obstructive sleep apnea syndrome," *European Archives of Oto-Rhino-Laryngology*, vol. 271, no. 11, p. 2949, 2014.
- [4] J. Durán, S. Esnaola, R. Rubio, and Á. Iztueta, "Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr," *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 3, part 1, pp. 685–689, 2001.
- [5] E. K. Larkin, C. L. Rosen, H. L. Kirchner et al., "Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration," *Circulation*, vol. 111, no. 15, pp. 1978–1984, 2005.
- [6] A. A. Meyer, G. Kundt, M. Steiner, P. Schuff-Werner, and W. Kienast, "Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors," *Pediatrics*, vol. 117, no. 5, pp. 1560–1567, 2006.
- [7] X. Wang, Y. Ouyang, Z. Wang, G. Zhao, L. Liu, and Y. Bi, "Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies," *International Journal of Cardiology*, vol. 169, no. 3, pp. 207–214, 2013.
- [8] N. Takama and M. Kurabayashi, "Influence of untreated sleep-disordered breathing on the long-term prognosis of patients

- with cardiovascular disease," *The American Journal of Cardiology*, vol. 103, no. 5, pp. 730–734, 2009.
- [9] M. R. Bootcov, A. R. Bauskin, S. M. Valenzuela, A. G. Moore, M. Bansal, and X. Y. He, "MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF- β superfamily," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 21, pp. 11514–11519, 1997.
- [10] T. Kempf, M. Eden, J. Strelau et al., "The transforming growth factor- β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury," *Circulation Research*, vol. 98, no. 3, pp. 351–360, 2006.
- [11] J. Xu, T. R. Kimball, J. N. Lorenz et al., "GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation," *Circulation Research*, vol. 98, no. 3, pp. 342–350, 2006.
- [12] T. Kempf, S. von Haehling, T. Peter et al., "Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure," *Journal of the American College of Cardiology*, vol. 50, no. 11, pp. 1054–1060, 2007.
- [13] D. A. Brown, S. N. Breit, J. Buring et al., "Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study," *The Lancet*, vol. 359, no. 9324, pp. 2159–2163, 2002.
- [14] B. M. Sanner, P. Kollhosser, N. Buechner, W. Zidek, and M. Tepel, "Influence of treatment on leptin levels in patients with obstructive sleep apnoea," *The European Respiratory Journal*, vol. 23, no. 4, pp. 601–604, 2004.
- [15] T. Ago and J. Sadoshima, "GDF15, a cardioprotective TGF- β superfamily protein," *Circulation Research*, vol. 98, no. 3, pp. 294–297, 2006.
- [16] K. C. Wollert, T. Kempf, B. Lagerqvist et al., "Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome," *Circulation*, vol. 116, no. 14, pp. 1540–1548, 2007.
- [17] A. Dominguez-Rodriguez, P. Abreu-Gonzalez, I. F. Hernandez-Baldero, P. Avanzas, and F. Bosa-Ojeda, "Change in growth differentiation factor 15, but not c-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome," *Mediators of Inflammation*, vol. 2014, Article ID 929536, 5 pages, 2014.
- [18] G. A. Bonaterra, S. Zügel, J. Thogersen et al., "Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury," *Journal of the American Heart Association*, vol. 1, no. 6, Article ID e002550, 2012.
- [19] T. Kempf, A. Zarbock, C. Widera et al., "GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice," *Nature Medicine*, vol. 17, no. 5, pp. 581–588, 2011.
- [20] A. Rohatgi, P. Patel, S. R. Das et al., "Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas heart study," *Clinical Chemistry*, vol. 58, no. 1, pp. 172–182, 2012.
- [21] G. Weinreich, T. E. Wessendorf, T. Erdmann et al., "Association of obstructive sleep apnoea with subclinical coronary atherosclerosis," *Atherosclerosis*, vol. 231, no. 2, pp. 191–197, 2013.
- [22] T. Inami, Y. Seino, T. Otsuka et al., "Links between sleep disordered breathing, coronary atherosclerotic burden, and cardiac biomarkers in patients with stable coronary artery disease," *Journal of Cardiology*, vol. 60, no. 3, pp. 180–186, 2012.
- [23] V. K. Somers, M. E. Dyken, M. P. Clary, and F. M. Abboud, "Sympathetic neural mechanisms in obstructive sleep apnea," *The Journal of Clinical Investigation*, vol. 96, no. 4, pp. 1897–1904, 1995.
- [24] T. Kempf, E. Björklund, S. Olofsson et al., "Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction," *European Heart Journal*, vol. 28, no. 23, pp. 2858–2865, 2007.
- [25] T. Kempf, A. Guba-Quint, J. Torgerson et al., "Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial," *European Journal of Endocrinology*, vol. 167, no. 5, pp. 671–678, 2012.
- [26] A. S. Gami, A. Svatikova, R. Wolk et al., "Cardiac troponin T in obstructive sleep apnea," *Chest*, vol. 125, no. 6, pp. 2097–2100, 2004.
- [27] A. Randby, S. K. Namtvedt, G. Einvik et al., "Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels," *Chest*, vol. 142, no. 3, pp. 639–646, 2012.
- [28] P. Calabró, J. T. Willerson, and E. T. Yeh, "Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells," *Circulation*, vol. 108, no. 16, pp. 1930–1932, 2003.
- [29] N. M. Punjabi and B. A. Beamer, "C-reactive protein is associated with sleep disordered breathing independent of adiposity," *Sleep*, vol. 30, no. 1, pp. 29–34, 2007.
- [30] R. Nadeem, J. Molnar, E. M. Madbouly et al., "Serum inflammatory markers in obstructive sleep apnea: a meta-analysis," *Journal of Clinical Sleep Medicine*, vol. 9, no. 10, pp. 1003–1012, 2013.
- [31] X. Xie, L. Pan, D. Ren, C. Du, and Y. Guo, "Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis," *Sleep Medicine*, vol. 14, no. 11, pp. 1139–1150, 2013.
- [32] T. S. Hall, T. E. Herrscher, P. Jarolim et al., "Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea," *Sleep Medicine*, vol. 15, no. 7, pp. 762–768, 2014.
- [33] C. A. M. Medeiros, V. M. S. de Bruin, G. M. Andrade, W. M. Coutinho, C. de Castro-Silva, and P. F. C. de Bruin, "Obstructive sleep apnea and biomarkers of inflammation in ischemic stroke," *Acta Neurologica Scandinavica*, vol. 126, no. 1, pp. 17–22, 2012.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

